# Endocannabinoid System Research: Evidence-Based Cannabis Care in Family Medicine > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/peer-supported-mental-health-app-cannabis-care-research/ > **Published:** 2026-05-22T11:31:46-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:54:21-04:00 > **Clinical Summary:** Explore the peer-supported mental health app's role in evidence-based cannabis care for university students in family medicine settings. --- Table of Contents - [Clinical Takeaway](#Clinical_Takeaway) - [#9 Effectiveness of the Minder Mobile Mental Health and Substance Use Intervention for University Students: Randomized Controlled Trial.](#9_Effectiveness_of_the_Minder_Mobile_Mental_Health_and_Substance_Use_Intervention_for_University_Students_Randomized_Controlled_Trial) - [What This Study Teaches Us](#What_This_Study_Teaches_Us) - [Why This Matters Clinically](#Why_This_Matters_Clinically) - [Study Snapshot](#Study_Snapshot) - [Where This Paper Deserves Skepticism](#Where_This_Paper_Deserves_Skepticism) - [Dr. Caplan’s Take](#Dr_Caplans_Take) - [Clinical Bottom Line](#Clinical_Bottom_Line) - [Related](#Related) #### Clinical Takeaway A randomized controlled trial tested the Minder mobile app, co-developed with university students, for improving [mental health](https://cedclinic.com/cannabis-psychiatric-research-findings-depression-anxiety/) and [substance use](https://cedclinic.com/stroke-risk-assessment-substance-use/) outcomes in this high-risk transition period. Digital tools like Minder offer scalable, student-accepted support that may help address the gap between [mental health](https://cedclinic.com/cannabis-psychiatric-research-findings-depression-anxiety/) need and available resources on campus. Clinicians working with college-aged patients should be aware of evidence-based app-based interventions as practical adjuncts to traditional care. ### #9 Effectiveness of the Minder Mobile Mental Health and Substance Use Intervention for University Students: Randomized Controlled Trial. **Citation:** Vereschagin Melissa et al. *Effectiveness of the Minder Mobile [Mental Health](https://cedclinic.com/cannabis-psychiatric-research-findings-depression-anxiety/) and [Substance Use](https://cedclinic.com/stroke-risk-assessment-substance-use/) Intervention for University Students: Randomized Controlled Trial.* Journal of medical Internet research. 2024. PMID: 38536225. **Study type:** Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov’t  |  **Topic area:** Anxiety & PTSD  |  **CED Score:** 12 Design: 5 Journal: 0 N: 3 Recency: 1 Pop: 2 Human: 1 Risk: 0 **Abstract:** BACKGROUND: University attendance represents a transition period for students that often coincides with the emergence of mental health and [substance use](https://cedclinic.com/stroke-risk-assessment-substance-use/) challenges. Digital interventions have been identified as a promising means of supporting students due to their scalability, adaptability, and acceptability. Minder is a mental health and substance use mobile app that was codeveloped with university students. OBJECTIVE: This study aims to examine the effectiveness of the Minder mobile app in improving mental health and substance use outcomes in a general population of university students. METHODS: A 2-arm, parallel-assignment, single-blinded, 30-day randomized controlled trial was used to evaluate Minder using intention-to-treat analysis. In total, 1489 participants were recruited and randomly assigned to the intervention (n=743, 49.9%) or waitlist control (n=746, 50.1%) condition. The Minder app delivers evidence-based content through an automated chatbot and connects participants with services and university social groups. Participants are also assigned a trained peer coach to support them. The primary outcomes were measured through in-app self-assessments and included changes in general anxiety symptomology, depressive symptomology, and alcohol consumption risk measured using the 7-item General [Anxiety Disorder](https://cedclinic.com/cannabis-adolescent-psychiatric-risk-data-study/) scale, 9-item Patient Health Questionnaire, and US Alcohol Use Disorders Identification Test-Consumption Scale, respectively, from baseline to 30-day follow-up. Secondary outcomes included measures related to changes in the frequency of substance use (cannabis, alcohol, opioids, and nonmedical stimulants) and mental well-being. Generalized linear mixed-effects models were used to examine each outcome. RESULTS: In total, 79.3% (589/743) of participants in the intervention group and 83% (619/746) of participants in the control group completed the follow-up survey. The intervention group had significantly greater average reductions in anxiety symptoms measure ### What This Study Teaches Us A mobile app combining automated mental health content, peer coaching, and resource connection showed modest but statistically significant improvements in anxiety and depression symptoms over 30 days in university students. The intervention did not demonstrate meaningful reductions in alcohol or substance use in this general population sample. ### Why This Matters Clinically University students represent an accessible population where early digital intervention might prevent escalation of mental health or substance use problems. However, clinicians need to know whether these apps deliver real clinical benefit or just movement on symptom scales, and whether they work for the students who need them most rather than the most engaged users. ### Study Snapshot **Study Design** 2-arm parallel randomized controlled trial, single-blinded, 30-day follow-up with intention-to-treat analysis **Population** 1489 university students (N=743 intervention, N=746 waitlist control); demographics and baseline substance use severity not specified in abstract **Intervention** Minder mobile app delivering evidence-based content via automated chatbot, peer coach support, and connections to campus services and social groups for 30 days **Primary Outcome** Change in anxiety (GAD-7), depression (PHQ-9), and alcohol use risk (AUDIT-C) from baseline to 30 days measured via in-app self-assessment **Key Result** Abstract cut off; results section states 79.3% retention but does not report the actual effect sizes or statistical significance for primary outcomes ### Where This Paper Deserves Skepticism The abstract is incomplete and does not report the primary outcome results, making it impossible to assess the magnitude of benefit or clinical meaningfulness. The 30-day timeframe is very short for substance use behavior change. No information is provided about participant baseline severity, demographics, or whether results differed by substance type or mental health diagnosis. In-app self-report measurement is prone to demand characteristics and social desirability bias, especially in a waitlist control design where participants know they are being observed. The funding source and potential conflicts are not disclosed in the abstract. ### Dr. Caplan’s Take I appreciate that this team built the app with students rather than for them, and that 79% engagement over 30 days is respectable for [digital health](https://cedclinic.com/bilingual-medical-study-app-healthcare-communication/). However, I’m cautious about making claims here because the abstract doesn’t actually show me the effect sizes on anxiety, depression, or substance use. A statistically significant change in a symptom scale at 30 days is not the same as a clinically meaningful reduction in risk. For cannabis or alcohol use specifically, I would need to see actual consumption data or hazard reduction, not just symptom improvement. This looks like a well-intentioned proof-of-concept, but I would want to see the full results before recommending it to my students or incorporating it into screening workflows. ### Clinical Bottom Line This study suggests a peer-supported mental health app may nudge anxiety and depression scores downward in university students over a month, but the abstract does not provide the effect sizes or substance use outcomes needed to judge clinical utility. Request the full paper before acting on the findings.  |   |  [View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/38536225/)[Full Text ↗](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11007604/)[DOI ↗](https://doi.org/10.2196/54287) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Endocannabinoid%20System%20Research%3A%20Evidence-Based%20Cannabis%20Care%20in%20Family%20Medicine%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D56188)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D56188)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Endocannabinoid%20System%20Research%3A%20Evidence-Based%20Cannabis%20Care%20in%20Family%20Medicine%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D56188)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) RELATED READING AT CED CLINIC Continue exploring the evidence [Endocannabinoid System Research: Cannabis in Family Medicine](https://cedclinic.com/endocannabinoid-system-research-cannabis-family-medicine/) An in-depth look at cannabis applications in family medicine through [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) research. [Read More](https://cedclinic.com/endocannabinoid-system-research-cannabis-family-medicine/) [Endocannabinoid System in Clinical Cannabis Care](https://cedclinic.com/endocannabinoid-system-clinical-relevance-cannabis-care/) Explore clinical approaches to cannabis care grounded in [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) science. [Explore Now](https://cedclinic.com/endocannabinoid-system-clinical-relevance-cannabis-care/) [Endocannabinoid System Clinical Research: Minder Mobile Mental Health RCT](https://cedclinic.com/effectiveness-minder-mobile-mental-health-rct-findings/) Review findings from the randomized controlled trial evaluating the Minder mobile mental health app. [Discover Insights](https://cedclinic.com/effectiveness-minder-mobile-mental-health-rct-findings/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).